Local ablation plus drug therapy for nasopharyngeal cancer spread to liver or lung
Tests local ablation with drug therapy in adults with a few liver or lung spots.
Plain-language title generated from the registry record
Registry title: Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma
Key facts
- Where
- Guangzhou, ChinaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with nasopharyngeal carcinoma whose cancer came back in the liver and/or lung, in no more than 5 small spots, at least 6 months after the first treatment.
- Age
- 18 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Nasopharyngeal carcinoma that spread to the liver and/or lung at least 6 months after the first treatment of the main tumor. No more than 5 spots, each 3 cm (1.2 in) or smaller, that can be treated by ablation. No spread to lymph nodes or other organs. ECOG performance status 0 or 1.
- Earlier treatment
- The main tumor must have been treated with curative treatment before. No earlier systemic treatment for the spread disease, such as gemcitabine plus cisplatin or a PD-1 inhibitor.
Main reasons for not taking part
- Another cancer within the last 3 years or at the same time
- Earlier gemcitabine plus cisplatin or PD-1 inhibitor treatment
- Severe liver, kidney, heart, lung or brain problems, or poorly controlled high blood pressure
- Bleeding problems that cannot be corrected, or serious bleeding in the last 30 days
- Expected survival of less than 3 months, or an organ transplant in the past
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07824856, who can take part
Where in China
- Sun Yat-sen University Cancer CenterGuangzhou, ChinaContact: Yi-Quan Jiang, MDNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Sun Yat-sen University
- Trial code
- NCT07824856
- Record updated
- 17 September 2026
- Original description
This single-center, open-label, randomized phase II trial evaluates whether CT-guided local ablation of liver and/or lung oligometastases, added to systemic therapy, improves the objective response rate compared with systemic therapy alone in patients with metachronous liver and/or lung oligometastases (no more than 5 lesions, each 3 cm or smaller) from nasopharyngeal carcinoma.Read full original descriptionShow less
Efficacy and Safety of Local Ablation Combined With Systemic Therapy for Metachronous Hepatic and/or Pulmonary Oligometastases From Nasopharyngeal Carcinoma: A Single-Center, Open-Label, Randomized Controlled Phase II Trial
This single-center, open-label, randomized phase II trial evaluates whether CT-guided local ablation of liver and/or lung oligometastases, added to systemic therapy, improves the objective response rate compared with systemic therapy alone in patients with metachronous liver and/or lung oligometastases (no more than 5 lesions, each 3 cm or smaller) from nasopharyngeal carcinoma.
Inclusion: Written informed consent to participate in the trial; Age 18 to 75 years, any sex; Histologically or cytologically confirmed nasopharyngeal carcinoma, with clinically diagnosed liver and/or lung metastases; Primary nasopharyngeal tumor cured after curative treatment, with no lymph node metastasis and no metastases outside the liver and lung (metachronous metastasis: distant metastasis detected at least 6 months after curative treatment of the primary tumor); No more than 5 liver and/or lung metastases, each 3 cm or smaller in diameter; Liver and/or lung metastases amenable to ablation; ECOG performance status 0 or 1; Adequate hematologic and organ function: absolute neutrophil count ≥1.5×10\^9/L; hemoglobin ≥70 g/L; platelet count ≥50×10\^9/L; white blood cell count ≥3.0×10\^9/L; serum albumin ≥28 g/L; total bilirubin ≤3.0 mg/dL; AST and ALT ≤5×ULN; serum creatinine ≤1.5×ULN; INR ≤2.3 (without anticoagulant therapy); No prior systemic therapy for metastatic disease (e.g., gemcitabine plus cisplatin chemotherapy or PD-1 inhibitor).
Exclusion: Clinically significant bleeding within 30 days before study entry; Urine protein ≥1 g/24 h (participants with ≥1+ proteinuria on dipstick must have 24-hour urine protein measured); prior organ transplantation; Anticoagulant and/or antiplatelet therapy (except novel oral anticoagulants such as dabigatran and rivaroxaban) not discontinued for more than 5-7 days before ablation; Other malignancy within the previous 3 years or concurrently; Prior gemcitabine plus cisplatin chemotherapy or PD-1 inhibitor therapy; History of hypersensitivity or intolerance to any study drug; Severe hepatic insufficiency, pulmonary fibrosis, or pulmonary hypertension; Poorly controlled infectious or radiation-induced inflammation around the lesion, skin infection at the puncture site, systemic infection, or fever >38.5 °C; Poorly controlled malignant pleural effusion; Uncorrectable coagulopathy or marked hematologic abnormality with evident bleeding tendency; Psychiatric disorder in an active episode; Poorly controlled hypertension: systolic blood pressure >150 mmHg and/or diastolic blood pressure >100 mmHg; Any other condition that, in the investigator's judgment, makes the patient unsuitable for the trial; Severe hepatic, renal, cardiac, pulmonary, or cerebral dysfunction; severe anemia, dehydration, or nutritional/metabolic disturbance that cannot be corrected in the short term; left ventricular ejection fraction <45%; History of congenital long QT syndrome, or corrected QT interval >480 ms (Fridericia); Estimated life expectancy less than 3 months.